论文部分内容阅读
为了进一步阐明人胃腺癌阿霉素耐药细胞系ＢＧＣ－８２３／ＤＯＸ耐药机理和特点，作者应用ＤＮＡ分子杂交、ＲＴ－ＰＣＲ、免疫组化和流式细胞技术进行了ＢＧＣ－８２３／ＤＯＸ多药耐药（ＭＤＲ１）、拓扑异构酶Ⅱα（ＴｏｐｏⅡα）、多药耐药相关蛋白基因的基因扩增、转录、表达分子水平检测以及细胞内阿霉素含量分析。结果表明，ＢＧＣ－８２３／ＤＯＸ亲本细胞具有原发耐药的特性，与消化道肿瘤较为相似。多药耐药是ＢＧＣ－８２３／ＤＯＸ主要的耐药机理。亲本细胞具有原发耐药ＢＧＣ－８２３／ＤＯＸ与亲本无原发耐药的阿霉素耐药细胞系相比，在耐药性质上有显著的差异。
In order to further elucidate the mechanism and characteristics of the human gastric adenocarcinoma doxorubicin-resistant cell line BGC-823/DOX, the author used BGC-823/DOX to perform DNA molecular hybridization, RT-PCR, immunohistochemistry and flow cytometry. Drug resistance (MDR1), topoisomerase IIα (TopoIIα), gene amplification of multidrug resistance-associated protein genes, transcription, expression at the molecular level, and intracellular adriamycin content analysis. The results showed that the BGC-823/DOX parental cells had the characteristics of primary drug resistance, which was similar to that of digestive tract tumors. Multidrug resistance is the main resistance mechanism of BGC-823/DOX. There was a significant difference in drug resistance between parental cells with primary drug resistance BGC-823/DOX and parental drug-resistant adriamycin-resistant cell lines without parental resistance.